Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
J Aerosol Med Pulm Drug Deliv. 2022 Apr;35(2):73-82. doi: 10.1089/jamp.2021.0045. Epub 2021 Dec 30.
Respiratory infections are increasingly difficult to treat due to the emergence of multidrug-resistant bacteria. Rediscovery and implementation of inhaled bacteriophage (phage) therapy as a standalone or supplement to antibiotic therapy is becoming recognized as a promising solution to combating respiratory infections caused by these superbugs. To ensure maximum benefit of the treatment, phages must remain stable during formulation as a liquid or powder and delivery using a nebulizer or dry powder inhaler. -targeting PEV phages were used as model phages to assess the feasibility of aerosolizing biologically viable liquid formulations using commercial nebulizers in the presence and absence of inhaled antibiotics. The advantages of powder formulations were exploited by spray drying to produce inhalable powders containing PEV phages with and without the antibiotic ciprofloxacin. The produced phage PEV20 and PEV20-ciprofloxacin powders remained stable over long-term storage and exhibited significant bacterial killing activities in a mouse lung infection model. These studies demonstrated that inhaled phage (-antibiotic) therapy has the potential to tackle respiratory infections caused by superbugs.
呼吸道感染由于多药耐药菌的出现而越来越难以治疗。重新发现和实施吸入噬菌体（噬菌体）治疗作为抗生素治疗的独立或补充方法，正被认为是对抗这些超级细菌引起的呼吸道感染的有前途的解决方案。为了确保治疗的最大益处，噬菌体在作为液体或粉末进行配方以及使用雾化器或干粉吸入器进行输送时必须保持稳定。-靶向 PEV 噬菌体被用作模型噬菌体，以评估在存在和不存在吸入性抗生素的情况下，使用商业雾化器将生物上可行的液体制剂气溶胶化的可行性。通过喷雾干燥来利用粉末制剂的优势，以生产含有 PEV 噬菌体和抗生素环丙沙星的可吸入粉末。生产的噬菌体 PEV20 和 PEV20-环丙沙星粉末在长期储存期间保持稳定，并在小鼠肺部感染模型中表现出显著的杀菌活性。这些研究表明，吸入噬菌体（-抗生素）治疗有可能解决由超级细菌引起的呼吸道感染。
